MB-ZLAB@EC2611A

Zai Lab Chairman Du Ying Sells $2.02M in ADS Shares, Holding Drops to 1.12 Million

Zai Lab's Drug Zoci Receives FDA Fast Track Designation for the Treatment of Extracranial Neuroendocrine Carcinoma

BOC International Downgrades Zai Lab's Rating and Target Price

Zai Lab Announces Q1 2026 Financial Results and R&D Progress

Zai Lab Q1 2026 Revenue Misses Expectations

ZAI LAB released FY2026 Q1 earnings on May 7 Pre-Market (BJT), actual revenue HKD 780.65 M (forecast HKD 806.52 M), actual EPS HKD -0.3918 (forecast HKD -0.361)

ZAI LAB to Release FY2026 Q1 Earnings on May 7 Pre-Market (BJT), Forecast Revenue HKD 881.68 M, EPS HKD -0.4258

BOA Securities Upgrades Revenue Forecasts for Zai Lab

Zai Lab Shifts Focus to Global Innovation Pipeline Valuation

UBS Downgrades Zai Lab's Q1 Sales Forecast but Raises Price Target

Zai Lab Announces Early Clinical Results of DLL3-targeted Antibody Drug Conjugate

RA Capital and RTW Investments Massive Investment in Zai Lab

Zai Lab Partners with Amgen for DLL3 Targeting ADC Clinical Trial

Zai Lab Reports FY2025 Results: Revenue Up, Net Loss Down

ZAI LAB to Release FY2025 Earnings on March 28 After-Market (BJT), Forecast Revenue HKD 3.639 B, EPS HKD -1.2448

BOA Securities Cuts Revenue Forecast for Zai Lab But Raises Target Price

Guotai Junan Maintains Overweight Rating on Zai Lab with Price Target

Citibank Downgrades Zai Lab's US Target Price

Zai Lab Reports Earnings and Product Development Plans

ZAI LAB released FY2025 annual earnings on February 26 Pre-Market (BJT), actual revenue HKD 3.588 B (forecast HKD 3.639 B), actual EPS HKD -1.2496 (forecast HKD -1.2448)

RADIANCE HLDGS

ANCHORSTONE

RIVERINE CHINA

REACH NEW HLDGS

FINELAND LIVING

NUR HOLDINGS

GOLDEN LEAF INT

UBOT HOLDING

MAN YUE TECH

ZLAB

09688

M Stanley has revised its target price for ZAI LABfrom HKD19.5 to HKD19, maintaining an Overweight rating. This adjustment follows updates to its financial model after the company's 1Q results, leading to a 5% reduction in revenue forecasts for 2026-2028. M Stanley projects ZAI LAB's 2026 revenue at USD488 million, with adjusted loss per share forecasts for 2026-2028. The broker notes that the impact of the target price cut is limited due to the reliance on terminal value in DCF models for biotech valuations.

- M Stanley updated its risk-reward assessment on ZAI LAB (09688.HK), lowering the target price from HKD 19.5 to HKD 19 while maintaining an Overweight rating.  
- This adjustment is based on financial model updates following the company’s 1Q results, resulting in a 5% revenue forecast reduction for 2026 to 2028.  
- M Stanley projects ZAI LAB’s 2026 revenue at USD 488 million and has revised its 2026-2028 loss per share forecasts upward, reflecting anticipated changes in biotech stock valuations.

AASTOCKS News

Zai Lab

ZAI LAB

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts ZAI LAB  TP to HKD19, Reflecting Post-1Q Results Forecast Revisions

ZAI LAB Limited; due to a significant decline in sales of the best-selling drug "Zellet," first-quarter revenue decreased by 6% year-on-year to USD 99.6 million, and net losses widened to USD 51 million. Sales of "Zellet" plummeted by 40% year-on-year to USD 30 million due to competition from generic drugs. Sales of the second-best-selling drug "Weiqijia" also declined, while sales of "Zesida" surged sevenfold. The company's stock price fell by 7.1% to HKD 15.5, with a cumulative increase of approximately 10.6% for the year

BambooWorks

News: Best-selling drug sales plummet, ZAI LAB's revenue declines

520690

516820

Zai Lab Ltd (HK:9688) reported Q1 2026 revenues of $99.6 million, impacted by seasonal dynamics and competition for ZEJULA and VYVGART. The company is preparing for the China launch of KarXT for schizophrenia and is undergoing regulatory review for TIVDAK. Positive Phase 3 data for povetacicept and elegrobart were highlighted, along with strong momentum in its R&D pipeline, particularly for zoci in oncology. The latest analyst rating is a Hold with a price target of HK$18.00. Zai Lab focuses on innovative therapies in oncology and immunology, with a market cap of HK$18.31B.

- Zai Lab Ltd reported first-quarter 2026 revenues of $99.6 million, impacted by seasonal dynamics and competition for key drugs.  
- The company is preparing for the China launch of KarXT for schizophrenia and has positive data for its ongoing projects, positioning itself for regional growth.  
- Zai Lab’s strong R&D pipeline includes promising developments in oncology and immunology, maintaining a market cap of HK$18.31 billion with a current analyst rating of Hold at a HK$18.00 price target.

Tip Ranks

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Huaan Hang Seng Biotech ETF

ICBCCS SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Amgen

Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches

SBIO

BofAS has raised its target price for Zai Labto HKD18.6 while maintaining a Neutral rating. The report highlights a 13.2% YoY increase in total sales of sample drugs, reaching RMB112.7 million in February. Notable sales include Niraparib, which saw a reduced YoY decline, and significant growth in omadacycline and ripretinib. The broker also increased its probability of success for ZL-1310 from 75% to 80%, leading to a 2% rise in the 2028 revenue forecast. The US share target price was raised from USD21.8 to USD24.

- BofAS reported Zai Lab's total sales of sample drugs in February reached RMB112.7 million, a 13.2% year-over-year increase.  
- Sales of Niraparib improved, with revenue of RMB49.6 million and a YoY decline narrowed to 2%.  
- The broker raised Zai Lab's long-term revenue projections and share price targets, maintaining a Neutral rating due to mixed product performance.

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

VG Health

VanEck Biotech ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Ark Genomic Revolution ETF

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BofAS Raises Zai Lab  TP to HKD18.6, Rating Neutral

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will announce its first quarter 2026 financial results and recent corporate updates on May 7, 2026, before U.S. market opening. A conference call and webcast will follow at 8:00 a.m. ET (8:00 p.m. HKT). Participants must register in advance for the call. Zai Lab is a biopharmaceutical company focused on innovative products in oncology, immunology, neuroscience, and infectious diseases.

- Zai Lab Limited will report its first quarter 2026 financial results and provide corporate updates on May 7, 2026.  
- A conference call and webcast will follow the announcement at 8:00 a.m. ET (8:00 p.m. HKT), with registration required in advance.  
- Zai Lab is a biopharmaceutical company focused on developing innovative products for unmet medical needs in oncology, immunology, neuroscience, and infectious diseases.

StockTitan

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 | ZLAB Stock News

BIDU

The Nasdaq Golden Dragon China Index initially fell 0.3%. Among popular Chinese concept stocks, EHang Intelligence, Tiger Brokers, VNET Group, and NIO initially dropped more than 2%, while Beike, Baidu, and Li Auto rose over 1%, and ZAI LAB gained 4.3%

Wallstreetcn

Baidu

NASDAQ Golden Dragon China Index

EHang

UP Fintech

Vnet

NIO Inc

NIO-SW

NIO Inc. USD OV

BIDU-SW

Li Auto

LI AUTO-W

BEKE-W

BIDU-SWR

09988

02076

02026

00700

The Nasdaq Golden Dragon China Index initially closed up 0.8%. Among popular Chinese concept stocks, PONY-W initially closed up 7.8%, ZAI LAB rose 5.7%, BOSS ZHIPIN-W gained 5.5%, Baidu increased 2.2%, Alibaba rose 1.5%, and Tencent advanced 0.8%. KWEB rose 0.9%

BABA-W

BOSS ZHIPIN-W

PONY-W

TENCENT

Pony AI

Kanzhun

Alibaba

Krne Csi China Internet

BABA-WR

Alibaba HK SDR 5to1

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Zai Lab Ltd has announced the granting of new equity awards under its 2024 Equity Incentive Plan, including share options and restricted share units to 45 option grantees and 471 RSU grantees. The plan includes 268,500 options priced at US$20.34 per ADS and 603,851 RSUs at no purchase price. These awards aim to retain and motivate employees, aligning their interests with long-term shareholder value. The current analyst rating for Zai Lab's stock (HK:9688) is a Hold with a price target of HK$15.00.

- Zai Lab Ltd has announced a new round of equity compensation under its 2024 Equity Incentive Plan, granting share options and restricted share units to employees.  
- This includes 268,500 options priced at US$20.34 per ADS and 603,851 RSUs, aimed at retaining staff and aligning their interests with shareholder value.  
- The latest analyst rating for Zai Lab’s stock is a Hold, with a price target of HK$15.00, reflecting ongoing competition for talent in the biopharmaceutical sector.

Zai Lab Expands Employee Equity Awards Under 2024 Incentive Plan

BYDDY

03896

The NASDAQ Golden Dragon China Index initially closed down 1.8%. Among popular Chinese concept stocks, WERIDE-W fell 9%, PONY-W fell 5.7%, KINGSOFT CLOUD fell 5.5%, BYD Company Limited fell 5.2%, NIO Inc. USD OV fell 4.4%, XPENG-W fell 3.8%, Alibaba fell 2.1%, and ZAI LAB rose 2.8%

MB-ZLAB@EC2611A(29025.HK)

M Stanley Cuts ZAI LAB TP to HKD19, Reflecting Post-1Q Results Forecast Revisions